CompletedPhase 3

MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia

China471 participantsStarted 2019-02-26

Plain-language summary

To compare the efficacy of Medroxyprogesterone Acetate with dydrogesterone in patients having endometrial hyperplasia (EH) without atypia.

Who can participate

Age range18 Years – 50 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Pathologically confirmed diagnosis of endometrial hyperplasia without atypia; * Consent informed and signed; * Able to follow treatment and take therapy in Obstetrics and Gynecology of Fudan University Exclusion Criteria: * Liver disease or liver tumor (benign or malignant) * Kidney disease or kidney tumor (benign or malignant) * Other malignancies in reproductive organs * Breast cancer or other progesterone-dependent tumors * History of endometrial atypical hyperplasia or endometrial cancer * Any contradictions against progesterone * Under treatment of progestin therapy or oral conceptive drugs one month before enrollment. * Pregnancy or suspicion of pregnancy * Ask for other treatment

What they're measuring

Pathological complete response (CR) rates

Timeframe: From date of randomization until the date of CR, assessed up to 6 months

Trial details

NCT IDNCT03675139

SponsorXiaojun Chen

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-05-14

View on ClinicalTrials.gov More Endometrial Hyperplasia Without Atypia trials